explore -WSS

explore

author：explore 2025-10-01 00:07:09 - browse：4648

Jeremey Wyatt ActiGraph

As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

The Pensacola, Fla.-based company creates devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： ALS advocates say criticism of new drugs misses bigger picture

WSS

AstraZeneca chief proposes a novel edit to the drug pricing bill

A new House health package & hospitals’ new site

Marvel Studios reveals new trailer for 'The Marvels': Watch here

The (many) problems with a new study criticizing cancer screening

A rare thyroid diagnosis led to unexpected, all

White House launches permanent pandemic office

focus

explore

leisure time

How to save PrEP access — and even expand it

Weighted lottery helped low

State Dept. review finds Biden bears some blame for Afghanistan failures

Why Novartis is changing the name of its research labs

Drug repurposing or repositioning? The language matters

What drug price negotiations mean for Medicare Part D

Peter Hotez and the public health issue of online harassment

How generative AI is inspiring dreams of a health data revolution

How to save PrEP access — and even expand it

A rare thyroid diagnosis led to unexpected, all

hotspot

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

Providers still hesitate to prescribe buprenorphine, study finds

Our daughter's deadly disease: trisomy 18. We wanted to protect her

Covid hospitalizations on the rise, Humana says

What drug price negotiations mean for Medicare Part D

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

knowledge

focus

focus

explore